RVMD - Revolution Medicines falls after early-stage data for cancer therapy
2023-10-23 09:03:43 ET
More on Revolution Medicines
- Revolution Medicines: A Big Pipeline In Need Of Big Data
- Revolution Medicines' Strategic Edge In RAS-Driven Oncology
- Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript
- Why did Revolution Medicines stock go up? Encouraging data for two drugs
- Revolution Medicines stock rallies 21% amid data presentations
For further details see:
Revolution Medicines falls after early-stage data for cancer therapy